RTTNews BiotechDoubao · 实盘不做把握 6/10不做原因:已被定价
北京时间·🕒 发布 15:28:31·⟳ 抓取 15:30:22 +1m51s·⚡ 决策 10-12 15:45:30 +15m08s·15.3 天前
逸達合作方長春金賽將在中國推出CAMCEVI 42mg，但NMPA批准事實已於10月9日經長春高新披露
藥品批准本身方向正面，但可交易主標的面臨同一催化的時間差問題：長春高新已於10月9日公告並在A股有所反應，中文媒體10月12日上午已廣泛報道，逸達直到臺北收盤後才發公司新聞稿；同時缺少本次批准對逸達的里程碑金、權利金或近期收入增量，風險回報不足以追價。
📄 原文RTTNews Biotech↗ 原文
Foresee Pharma's Partner GenSci To Launch CAMCEVI 42 Mg In China
Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…
不做 逸達生技（6576.TWO）
NMPA批准事實已由中國合作方母公司於10月9日披露，逸達收盤後新聞稿是延遲確認；本次未披露即時里程碑金或收入指引，且行情工具無法核驗10月12日台股是否已提前反應，不適合在次一開盤追多。
不做 長春高新（000661.SZ）
子公司獲批已於10月9日正式公告且A股當日反應，10月12日RTT訊息到達時A股已收盤；單一新藥對大型母公司短期收入和利潤彈性未量化，隔日再追的風險回報不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
CAMCEVI 42mg獲NMPA批准是逸達與長春金賽的正面商業化里程碑，但核心批准事實已由長春高新10月9日正式披露，10月12日RTT/逸達新聞稿更像跨市場確認而非全新增量；在經濟權益和A股/台股實際漲幅未能量化前不追多。
消息传播链
- 長春高新公告控股子公司金賽藥業收到甲磺酸亮丙瑞林注射液（6M）《藥品註冊證書》，這是本次NMPA批准最早的可交易公開披露。市场反应:長春高新2026-10-09收盤上漲3.86%至71.90元，表明A股至少已部分反應。
- 財聯社等中文媒體在10月12日上午報道金賽藥業六個月長效亮丙瑞林獲批，消息在台股收盤前已可被跨市場投資者獲得。
- 逸達在臺北市場10月12日收盤後正式確認合作方將在中國推出CAMCEVI 42mg，並補充乳腺癌補充申請已獲受理。
- RTTNews轉述逸達說法，時間晚於長春高新公告和公司新聞稿，不構成首發事實。
关键理由
- CAMCEVI 42mg在中國從註冊審評進入批准上市狀態，並由金賽藥業負責商業化，降低了逸達中國授權資產的監管不確定性。
- 中國是首個六個月長效亮丙瑞林皮下製劑的稀缺市場，後續還可能延伸至中樞性性早熟及絕經前乳腺癌適應症。
主要风险
- 批准到實際處方放量還取決於招標、醫院准入、定價與醫保，新聞稿沒有給出銷售指引或逸達可收取的即時里程碑金。
- 長春高新10月9日公告及10月12日中文媒體擴散可能已使台股和A股相關預期部分定價，收盤後追新聞稿存在隔日高開低走風險。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-20 · 影响 weakens
自家案例庫和公披露顯示長春高新2026年上半年收入、利潤大幅下滑並計提管線減值，雖不抵消本次批准，但說明單一新品面對的公司基數和風險偏好較弱。
检索:長春高新 2026 半年报 收入 净利润 下滑 GenSci034 减值 - 做多前查反向 · 来源 web · 日期 2026-10-12 · 影响 weakens
公司新聞稿和RTT報道均未披露本次批准對應的即時里程碑金、保底款或收入預測，無法確認短期財務materiality。
检索:Foresee GenSci CAMCEVI China approval milestone royalty amount October 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-10-09 · 影响 weakens
A股在正式公告當日已上漲3.86%，且10月12日媒體再次擴散，跨市場追逸達的剩餘edge受限。
检索:長春高新 甲磺酸亮丙瑞林 6M 获批 10月9日 股价 3.86% 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足加上核心事實提前披露，使結論偏向不追價，而不是依據不可驗證的歷史漲幅開倉。
方向:找到同一公司同藥物FDA批准及同藥物其他適應症臨床成功先例，方向上支持監管里程碑為正面，但未能取得台股真實K線。
涨幅量级:event_study對兩條先例均返回no_bars，缺乏乾淨的aligned價格樣本，不能用歷史中位數設定止盈止損。
形态:無法量化是否反復高開低走；但本次中國批准已在合作方A股公告層面提前曝光，見光死風險只能以高price-in風險處理。
历史先例(按相似度)
- 相似度 7/10 6576.TWO 2025-08-29 逸達宣布CAMCEVI ETM獲FDA批准用於晚期前列腺癌，由Accord BioPharma主導美國商業化。 原文 ↗
原計劃測量6576.TWO在新聞稿後1/3/5個交易日表現。
相似度依据:同一藥物CAMCEVI、同一公司、同為前列腺癌監管批准，但市場從中國變為美國，且美國商業化合作方與經濟條款不同。
经验:同藥物監管批准可作為風險消除事件，但需用真實台股K線確認是否見光死；本次工具未取回價格，不能機械套用。 - 相似度 5/10 6576.TWO 2026-05-27 逸達宣布CASPPIAN三期完成並確認94%患者達到LH抑制，支持六個月給藥用於中樞性性早熟。 原文 ↗
原計劃測量6576.TWO在臨床讀出後1/3/5個交易日表現。
相似度依据:同一藥物和六個月劑型、同一公司，但事件是CPP適應症III期陽性讀出而非前列腺癌中國獲批，階段更早。
经验:臨床成功與批准上市都可能推升管線預期，但臨床讀出的不確定性和後續審批風險高於本次批准，不可直接用於設定漲跌幅。
工具执行结果 · 成功 22 · 降级 0 · 失败 3 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`6576 two leuprolide mesylate 6-month depot china marketing authorization changchun genescience | camcevi 42mg 长春金赛 中国 获批 前列腺癌 | foresee pharmaceuticals gensci camcevi 42 mg china n`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - web_search 成功 doubao_search · 2,343 ms
豆包搜索结果（原始查询:Foresee Pharmaceuticals CAMCEVI 42 mg China NMPA GenSci approval October 12 2026；API SearchType:web） - web_search 成功 doubao_search · 1,804 ms
豆包搜索结果（原始查询:Foresee Pharmaceuticals GenSci CAMCEVI China license agreement royalties milestones leuprolide mesylate；API SearchType:web） - web_search 成功 doubao_search · 1,812 ms
豆包搜索结果（原始查询:长春金赛药业 CAMCEVI 42mg 中国 NMPA 获批 亮丙瑞林 甲磺酸；API SearchType:web） - kb_search 失败 stock_tools HTTP · 60 ms
kb_search 服务暂不可用；这不是一条知识库命中。 - stock_quote 失败 stock_tools HTTP · 7 ms
行情服务暂不可用；本次无法核验该标的价格和可执行条件。请基于其余证据继续判断并明确标注行情降级；不得仅因工具故障自动给出 AVOID 或 ENTER，也不得编造价位。 - normalize_ticker 成功 stock_tools HTTP · 5 ms
{ - web_search 成功 doubao_search · 5,991 ms
豆包搜索结果（原始查询:site:foreseepharma.com 6576 GenSci CAMCEVI China licensing agreement upfront milestone royalty；API SearchType:web） - web_search 成功 doubao_search · 2,777 ms
豆包搜索结果（原始查询:Foresee Pharmaceuticals GeneScience exclusive license CAMCEVI China US$ million 2021；API SearchType:web） - web_search 成功 doubao_search · 2,650 ms
豆包搜索结果（原始查询:6576 智擎 長春金賽 CAMCEVI 中國 授權 里程碑 權利金；API SearchType:web） - web_search 成功 doubao_search · 6,682 ms
豆包搜索结果（原始查询:長春高新 甲磺酸亮丙瑞林注射液 6M 药品注册证书 2026 10 09 智擎 授权；API SearchType:web） - search_case_library 成功 stock_tools HTTP · 68 ms
{"result": "search_case_library「000661.SZ,6576.TWO」—— 与这些标的相关的自家决策案例(本页 12 条,该标的全历史相关记录共 64 条；ENTER 只按该标的自己的腿统计):\n◆ 000661.SZ：相关历史决策 64 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过\n◆ 6576.TWO：相关历史决策 0 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过\n【对所查标的真 ENTER 过的:0 条 —— 相关案例里没有该标的自己的 ENTER 腿】\n【 - direct_instrument_candidates 成功 stock_tools HTTP · 9 ms
{ - web_search 成功 doubao_search · 2,958 ms
豆包搜索结果（原始查询:"Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci" "$" million；API SearchType:web） - web_search 成功 doubao_search · 1,046 ms
豆包搜索结果（原始查询:"GenSci" "CAMCEVI" "upfront" OR "milestone" Foresee；API SearchType:web） - web_search 成功 doubao_search · 1,680 ms
web_search「"長春金賽" "逸達" "CAMCEVI" 美金 授權」无结果。 - web_search 成功 doubao_search · 1,551 ms
web_search「"逸達" "長春金賽" "6個月" 前列腺癌 中國 授權金」无结果。 - web_search 成功 doubao_search · 7,302 ms
豆包搜索结果（原始查询:6576 Foresee stock reaction NMPA approval CAMCEVI China October 12 2026；API SearchType:web） - web_search 成功 doubao_search · 8,181 ms
豆包搜索结果（原始查询:Foresee Pharmaceuticals CAMCEVI FDA approval stock reaction August 2025 6576；API SearchType:web） - web_search 成功 doubao_search · 1,892 ms
豆包搜索结果（原始查询:site:prnewswire.com Foresee CAMCEVI China phase 3 primary endpoint prostate cancer February 2024 6576；API SearchType:web） - web_search 成功 doubao_search · 1,379 ms
web_search「site:foreseepharma.com/en/news CAMCEVI China prostate cancer primary endpoint February 2024 Foresee GenSci」无结果。 - web_search 成功 doubao_search · 2,472 ms
豆包搜索结果（原始查询:Foresee Pharmaceuticals China registration clinical trial CAMCEVI 42 mg prostate cancer primary endpoint 2024 stock；API SearchType:web） - web_search 成功 doubao_search · 1,497 ms
豆包搜索结果（原始查询:长春高新 药品注册证书 创新药 获批 次日 股价 2026 长效 亮丙瑞林 6M 10月9日；API SearchType:web） - event_study 失败 stock_tools HTTP · 12 ms
no precedent bars (sources returned nothing for the proposed events)
原文全文
展开原文 · 6,980 字
Foresee Pharma's Partner GenSci To Launch CAMCEVI 42 Mg In China
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Quick Facts
Foresee Pharma's Partner GenSci To Launch CAMCEVI 42 Mg In China
By
RTTNews Staff Writer
✉
Published:
10/12/2026 3:28 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Foresee Pharmaceuticals (6576.TWO) said it was notified by licensing partner, Changchun GeneScience Pharmaceutical, that China's National Medical Products Administration has approved the Marketing Authorization Application for CAMCEVI 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, for the treatment of adult patients with advanced prostate cancer. CAMCEVI is exclusively licensed to GenSci for commercialization in China across all current and pipeline indications, including advanced prostate cancer, central precocious puberty, and premenopausal breast cancer.
GenSci submitted a supplemental New Drug Application in May 2026 for leuprolide mesylate injectable emulsion for the additional indication of premenopausal breast cancer, which has been accepted by the NMPA for substantive review.
At prior close on Taipei Exchange, Foresee shares were trading at NT$78.20.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Next Story
Latest Updates on Middle East War
Crude Oil Prices Moderately Higher After Yesterday's Spike
October 09, 2026 14:44 ET
Sen. Murphy Says Hegseth Covering Up Cost And Damages Of Iran War
October 09, 2026 07:35 ET
U.S. Stocks Close Mostly Lower On Spike In Oil Prices, OpenAI Revenue Concerns
October 08, 2026 16:17 ET
U.S. Stocks Mostly Lower As Crude Oil Prices Spike
October 08, 2026 11:19 ET
Renewed Spike In Crude Oil Prices May Weigh On Wall Street
October 08, 2026 08:50 ET
View More
The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the priva
October 09, 2026 15:35 ET
The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.
View More Videos
RELATED NEWS
Foresee Pharma's Partner GenSci To Launch CAMCEVI 42 Mg In China
Latest Updates on COVID-19
View More
Most Read
Most Emailed
Alimentation Couche-Tard To Buy Irving Oil Retail Assets In Québec, Ontario
October 09, 2026 10:19 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Delta Stock Drops On Cautious Earnings View In Q4 & FY26 After Weak Q3
October 09, 2026 09:40 ET
Nvidia-backed Australian AI Firm Firmus Scraps IPO Over Market Conditions
October 09, 2026 07:54 ET
Crescent Energy To Buy Devon's Eagle Ford Assets For $3.85 Bln; Launches $1 Bln Stock Offering
October 08, 2026 07:53 ET
Verizon, AT&T And T-Mobile Shares Plunge As SpaceX Strikes Spectrum Deal To Expand Starlink Mobile
October 09, 2026 17:32 ET
DCC Energy Agrees To Sell Nexora To One Equity Partners For $725 Mln
October 09, 2026 02:30 ET
Hexagon To Buy Rocscience For $535 Mln
October 09, 2026 02:46 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
Starbucks Explores Takeover Of Chipotle In Potential Record Restaurant Deal
October 08, 2026 17:01 ET
Microchip Technology Acquires VORAGO Technologies For Undisclosed Sum
October 09, 2026 09:14 ET
Natera's Multi-cancer Early Detection Assay Granted Breakthrough Device Designation By FDA
October 09, 2026 08:17 ET
Netflix Reportedly Plans To Lay Off 5% Of Its Workforce
October 09, 2026 11:17 ET
LG Electronics Q3 Prelim. Operating Income, Revenues Rise; Stock Drops
October 07, 2026 00:57 ET
Teva Pharmaceutical Stock Rises 6% After FDA Approves Monthly Schizophrenia Treatment
October 09, 2026 11:24 ET
Waystream Group Q3 Sales Increase
October 07, 2026 01:14 ET
Alignment Healthcare Stock Falls 17% On 2027 Medicare Star Ratings
October 09, 2026 11:26 ET
Intact Financial Projects Total Pre-tax Catastrophe Losses Of About C$660 Mln In Q3
October 07, 2026 01:15 ET
Toro Slips To Loss In Q2, Shares Down By Over 14%
October 09, 2026 12:02 ET
Ballard Secures 4.8MW Order From Siemens Mobility To Power Romanian Hydrogen Trains
October 07, 2026 01:39 ET
VEON's Banglalink Launches Starlink Satellite-to-mobile In Bangladesh
October 09, 2026 12:12 ET
Lunnon Metals Notes BHP Deal To Sell Kambalda Nickel Concentrator To Gold Fields
October 07, 2026 01:43 ET
Avient Stock Falls 5% After Appointing Mike Frank As CEO
October 09, 2026 12:33 ET
Netcall PLC Profit Falls In Full Year
October 07, 2026 02:09 ET
Editors Pick
Delta Stock Drops On Cautious Earnings View In Q4 & FY26 After Weak Q3
October 09, 2026 09:40 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Loading...
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Quick Facts
Foresee Pharma's Partner GenSci To Launch CAMCEVI 42 Mg In China
By
RTTNews Staff Writer
✉
Published:
10/12/2026 3:28 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Foresee Pharmaceuticals (6576.TWO) said it was notified by licensing partner, Changchun GeneScience Pharmaceutical, that China's National Medical Products Administration has approved the Marketing Authorization Application for CAMCEVI 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, for the treatment of adult patients with advanced prostate cancer. CAMCEVI is exclusively licensed to GenSci for commercialization in China across all current and pipeline indications, including advanced prostate cancer, central precocious puberty, and premenopausal breast cancer.
GenSci submitted a supplemental New Drug Application in May 2026 for leuprolide mesylate injectable emulsion for the additional indication of premenopausal breast cancer, which has been accepted by the NMPA for substantive review.
At prior close on Taipei Exchange, Foresee shares were trading at NT$78.20.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Next Story
Latest Updates on Middle East War
Crude Oil Prices Moderately Higher After Yesterday's Spike
October 09, 2026 14:44 ET
Sen. Murphy Says Hegseth Covering Up Cost And Damages Of Iran War
October 09, 2026 07:35 ET
U.S. Stocks Close Mostly Lower On Spike In Oil Prices, OpenAI Revenue Concerns
October 08, 2026 16:17 ET
U.S. Stocks Mostly Lower As Crude Oil Prices Spike
October 08, 2026 11:19 ET
Renewed Spike In Crude Oil Prices May Weigh On Wall Street
October 08, 2026 08:50 ET
View More
The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the priva
October 09, 2026 15:35 ET
The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.
View More Videos
RELATED NEWS
Foresee Pharma's Partner GenSci To Launch CAMCEVI 42 Mg In China
Latest Updates on COVID-19
View More
Most Read
Most Emailed
Alimentation Couche-Tard To Buy Irving Oil Retail Assets In Québec, Ontario
October 09, 2026 10:19 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Delta Stock Drops On Cautious Earnings View In Q4 & FY26 After Weak Q3
October 09, 2026 09:40 ET
Nvidia-backed Australian AI Firm Firmus Scraps IPO Over Market Conditions
October 09, 2026 07:54 ET
Crescent Energy To Buy Devon's Eagle Ford Assets For $3.85 Bln; Launches $1 Bln Stock Offering
October 08, 2026 07:53 ET
Verizon, AT&T And T-Mobile Shares Plunge As SpaceX Strikes Spectrum Deal To Expand Starlink Mobile
October 09, 2026 17:32 ET
DCC Energy Agrees To Sell Nexora To One Equity Partners For $725 Mln
October 09, 2026 02:30 ET
Hexagon To Buy Rocscience For $535 Mln
October 09, 2026 02:46 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
Starbucks Explores Takeover Of Chipotle In Potential Record Restaurant Deal
October 08, 2026 17:01 ET
Microchip Technology Acquires VORAGO Technologies For Undisclosed Sum
October 09, 2026 09:14 ET
Natera's Multi-cancer Early Detection Assay Granted Breakthrough Device Designation By FDA
October 09, 2026 08:17 ET
Netflix Reportedly Plans To Lay Off 5% Of Its Workforce
October 09, 2026 11:17 ET
LG Electronics Q3 Prelim. Operating Income, Revenues Rise; Stock Drops
October 07, 2026 00:57 ET
Teva Pharmaceutical Stock Rises 6% After FDA Approves Monthly Schizophrenia Treatment
October 09, 2026 11:24 ET
Waystream Group Q3 Sales Increase
October 07, 2026 01:14 ET
Alignment Healthcare Stock Falls 17% On 2027 Medicare Star Ratings
October 09, 2026 11:26 ET
Intact Financial Projects Total Pre-tax Catastrophe Losses Of About C$660 Mln In Q3
October 07, 2026 01:15 ET
Toro Slips To Loss In Q2, Shares Down By Over 14%
October 09, 2026 12:02 ET
Ballard Secures 4.8MW Order From Siemens Mobility To Power Romanian Hydrogen Trains
October 07, 2026 01:39 ET
VEON's Banglalink Launches Starlink Satellite-to-mobile In Bangladesh
October 09, 2026 12:12 ET
Lunnon Metals Notes BHP Deal To Sell Kambalda Nickel Concentrator To Gold Fields
October 07, 2026 01:43 ET
Avient Stock Falls 5% After Appointing Mike Frank As CEO
October 09, 2026 12:33 ET
Netcall PLC Profit Falls In Full Year
October 07, 2026 02:09 ET
Editors Pick
Delta Stock Drops On Cautious Earnings View In Q4 & FY26 After Weak Q3
October 09, 2026 09:40 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Loading...
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
31f327b225· 2026-10-12 15:45 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前